» Articles » PMID: 10087012

Molecular and Ligand-binding Characterization of the Sigma-receptor in the Jurkat Human T Lymphocyte Cell Line

Overview
Specialty Pharmacology
Date 1999 Mar 23
PMID 10087012
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

The sigma binding site present in the Jurkat human T lymphocyte cell line was investigated. Jurkat cell membranes were found to have a single saturable binding site for [3H]haloperidol, a sigma ligand (dissociation constant, 3.9 +/- 0.3 nM). The binding of [3H]haloperidol was inhibited by several sigma ligands. Northern analysis and reverse transcription-polymerase chain reaction provided evidence for the expression of the recently cloned type 1 sigma-receptor (sigma-R1) in Jurkat cells. The sigma-R1 cDNA cloned from these cells was functional in heterologous expression systems. When expressed in mammalian cells, the cDNA-induced binding was saturable with dissociation constants of 1.9 +/- 0.3 nM for [3H]haloperidol and 12 +/- 2 nM for (+)-pentazocine. The binding of [3H]progesterone, a putative endogenous ligand to sigma-R1, to the Jurkat cell sigma-receptor could be directly demonstrated by using heterologously expressed sigma-R1 cDNA. The binding of [3H]progesterone was saturable, with a dissociation constant of 88 +/- 7 nM. Progesterone and haloperidol interacted with the receptor competitively. Reverse transcription-polymerase chain reaction also produced evidence for the existence of an alternatively spliced sigma-R1 variant in Jurkat cells. This splice variant was found to be nonfunctional in ligand binding assays. This constitutes the first report on the molecular characterization of the sigma-receptor in immune cells.

Citing Articles

SAL0114: a novel deuterated dextromethorphan-bupropion combination with improved antidepressant efficacy and safety profile.

Xiao Y, Hu X, Xing W, Yan J, Wang R, Li X Front Pharmacol. 2024; 15:1464564.

PMID: 39386030 PMC: 11462627. DOI: 10.3389/fphar.2024.1464564.


Sigma Receptors: Novel Regulators of Iron/Heme Homeostasis and Ferroptosis.

Nguyen N, Jaramillo-Martinez V, Mathew M, Suresh V, Sivaprakasam S, Bhutia Y Int J Mol Sci. 2023; 24(19).

PMID: 37834119 PMC: 10572259. DOI: 10.3390/ijms241914672.


BS148 Reduces the Aggressiveness of Metastatic Melanoma via Sigma-2 Receptor Targeting.

Sorbi C, Belluti S, Atene C, Marocchi F, Linciano P, Roy N Int J Mol Sci. 2023; 24(11).

PMID: 37298633 PMC: 10253401. DOI: 10.3390/ijms24119684.


Sigma-1 Receptor Signaling: In Search of New Therapeutic Alternatives for Cardiovascular and Renal Diseases.

Munguia-Galaviz F, Miranda-Diaz A, Cardenas-Sosa M, Echavarria R Int J Mol Sci. 2023; 24(3).

PMID: 36768323 PMC: 9916216. DOI: 10.3390/ijms24031997.


Safe and Efficient Sigma1 Ligand: A Potential Drug Candidate for Multiple Sclerosis.

Oxombre B, Madouri F, Journe A, Ravez S, Woitrain E, Odou P Int J Mol Sci. 2022; 23(19).

PMID: 36233193 PMC: 9569529. DOI: 10.3390/ijms231911893.